Pluristem Therapeutics (PSTI) Receives Approval From Indian Ministry of Health for Use of PLX Cells in Phase II Trial for Treatment of Buerger's Disease  
8/16/2012 9:14:47 AM

HAIFA, Israel, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has received permission from the Indian Ministry of Health to proceed with a Phase II clinical trial for the treatment of thromboangiitis obliterans (Buerger's disease). This Phase II trial will be potentially followed by a larger multi-national Phase III study in the U.S., Europe and India.